NewAmsterdam Pharma Company N.V. (NAMSW) Net margin 2022–2025
NewAmsterdam Pharma Company N.V. (NAMSW) net profit margin by fiscal year — reported net income divided by reported revenue.
-905.7%FY2025 · since FY2022: -22.0% → -905.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -905.7% | -375.5 pp |
| FY2024 | -530.3% | +725.5 pp |
| FY2023 | -1255.8% | -1233.7 pp |
| FY2022 | -22.0% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMSW financial trends
NAMSW RevenueNAMSW Net incomeNAMSW Gross profitNAMSW Gross marginNAMSW Operating incomeNAMSW Operating marginNAMSW Operating cash flowNAMSW Free cash flowNAMSW Capital expendituresNAMSW Return on equityNAMSW Stock buybacksNAMSW Dividends paidNAMSW Total assetsNAMSW Total liabilitiesNAMSW Shareholders’ equityNAMSW overview →